Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion

Expert panel discussion on on the use of palbociclib in endocrine-resistant breast cancer. Learn about the clinical trial and optimize treatment strategies.

Speakers : Dr. Srinivas K G , Dr. Abhaya Kumar S M ,Dr. Vishwanath S

A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months

Join Dr. Srinivas K G, Dr. Abhaya Kumar S M, and Dr. Vishwanath S in a panel discussion on clinical trial endpoints for tumors with PPS > 12 months.

Speakers : Dr. Srinivas K G , Dr. Abhaya Kumar SM , Dr. Vishwanath S

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis

Discover real-world clinical outcomes, key findings, and expert insights for optimizing patient care. Watch now for evidence-based oncology perspectives!

Speakers : Dr. Srinivas K G

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

Explore how CDK4/6 inhibitors are transforming HR+/HER2- advanced breast cancer treatment in post-menopausal women.

Speakers : Dr. Srinivas K G , Dr. Abhaya Kumar S M

Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer

Discover how CDK4/6 inhibitors revolutionized HR+/HER2- metastatic breast cancer treatment in this expert analysis of the PALOMA-2 trial by Dr. Srinivas K G.

Speakers : Dr. Srinivas K G

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

Explore expert insights from Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja on the latest treatment strategies for relapsed/refractory adult B-cell ALL.

Speakers : Dr. Pawan Kumar Singh ,Dr. Roshan Dixit ,Dr. Manisha Jain ,Dr. Avruti Baweja

Cost Burden/ Burden of Hospitalization For R/R ALL Patients

Explore expert insights from Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja on the cost and hospitalization burden for R/R ALL patients.

Speakers : Dr. Pawan Kumar Singh , Dr. Manisha Jain , Dr. Roshan Dikshit , Dr. Avriti Baveja

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

Explore the long-term survival outcomes of iontuzumab-treated patients in the INO-VATE trial with experts Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja.

Speakers : Dr. Pawan Kumar Singh , Dr. Manisha Jain , Dr. Roshan Dikshit , Dr. Avriti Baveja

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

Explore expert insights from Dr. Pawan Kumar Singh, Dr. Roshan Dikshit, Dr. Manisha Jain, and Dr. Avriti Baveja on Iontuzumab’s impact on CR/CRi rates and MRD negativity in leukemia.

Speakers : Dr. Pawan Kumar Singh , Dr. Manisha Jain , Dr. Roshan Dikshit , Dr. Roshan Dikshit , Dr. Avriti Baveja

What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?

Learn about CAR T-cell therapy, bispecific antibodies, and personalized treatment strategies. Watch now for cutting-edge recommendations!

Speakers : Dr. Pawan Kumar Singh , Dr. Manisha Jain , Dr. Roshan Dikshit , Dr. Avriti Baveja


Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Retired Olympic athletes at greater risk of skin cancer and osteoarthritis, research reveals

2.

Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer

3.

Celebrity Cancers Stoking Fear? Cisplatin Shortage Ends; Setback for Anti-TIGIT

4.

Year in Review: Non-Small Cell Lung Cancer

5.

Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot